A systematic review of atopic dermatitis - pathomechanism, diagnosis and topical treatment
DOI:
https://doi.org/10.12775/QS.2025.45.66432Keywords
Atopic dermatitis, Eczema, SCORAD, genetic testing, topical treatmentAbstract
Introduction: Atopic dermatitis (AD), also known as eczema, is a chronic, recurrent inflammatory skin disease characterized by dryness, itching and rashes. It is one of the most common dermatological diseases, affecting both children and adults. The pathogenesis of AD is complex and involves a defect in the epidermal barrier, immune system dysfunction and changes in the composition of the skin microbiota. Various therapeutic approaches are used to treat AD, including skin moisturizers, glucocorticosteroids, topical calcineurin inhibitors, PDE-4 inhibitors, JAK inhibitors, and phototherapy. The increasing number of AD cases is a serious medical problem that affects not only dermatology and allergology, but also pediatrics and family medicine. AD therapy should effectively eliminate the symptoms of the disease, prevent exacerbations, complications, and improve patients' quality of life. [1,2,3,4]
Research objective: The objective of this study is to review the literature on atopic dermatitis, its pathomechanism, and the difficulties associated with its diagnosis and treatment.
Conclusions: Atopic dermatitis is a chronic skin disease with complex pathogenesis, involving epidermal barrier defect, immune disorders, and microbiota dysbiosis. Diagnosis is based on clinical presentation and severity scales, as there are no specific biomarkers. Patient education, elimination of exacerbating factors and individualization of therapy are key. Modern medications and educational programs improve patients' quality of life and allow for better disease control. Continuous research will allow for a better understanding of the pathophysiology of atopic dermatitis and the development of effective therapeutic strategies that can contribute to long-term control of the disease.
References
1. Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387:1109.
2. Gościńska A, Będzichowska A., Lipińska-Opałka A., Atopic dermatitis and the human skin microbiota Pediatr Med Rodz 2023, 19 (2), p. 78–82
3. Shi B, Bangayan NJ, Curd E et al.: The skin microbiome is different in pediatric versus adult atopic dermatitis. J Allergy Clin Immunol 2016; 138: 1233–1236.
4. Nowicki RJ, Trzeciak M, Kaczmarski M, et al. Atopic dermatitis. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allergology, Polish Pediatric Society and Polish Society of Family Medicine. Part II. Systemic treatment and new therapeutic methods. Dermatology Review/Przegląd Dermatologiczny. 2019;106(5):475-485. doi:10.5114/dr.2019.89995.
5. Kuo IH, Yoshida T, De Benedetto A, Beck LA. The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol. 2013 Feb;131(2):266-78. doi: 10.1016/j.jaci.2012.12.1563.
6. Menon GK, Cleary GW, Lane ME. The structure and function of the stratum corneum. Int J Pharm. 2012 Oct 1;435(1):3-9. doi: 10.1016/j.ijpharm.2012.06.005
7. Marks JG, Miller JJ, ookingbill and Marks' Principles of Dermatology (Sixth Edition), Elsevier, 2019, 2-10, ISBN 9780323430401, https://doi.org/10.1016/B978-0-323-43040-1.00002-6.
8. Sroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int J Mol Sci. 2021 Apr 16;22(8):4130. doi: 10.3390/ijms22084130.
9. Moosbrugger-Martinz V, Leprince C, Méchin MC, Simon M, Blunder S, Gruber R, Dubrac S. Revisiting the Roles of Filaggrin in Atopic Dermatitis. Int J Mol Sci. 2022 May 10;23(10):5318. doi: 10.3390/ijms23105318.
10. Bakker D, de Bruin-Weller M, Drylewicz J, van Wijk F, Thijs J. Biomarkers in atopic dermatitis. J Allergy Clin Immunol. 2023 May;151(5):1163-1168. doi: 10.1016/j.jaci.2023.01.019
11. Furue M. Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis. Int J Mol Sci. 2020 Jul 29;21(15):5382. doi: 10.3390/ijms21155382
12. Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020 Apr 20;21(8):2867. doi: 10.3390/ijms21082867.
13. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjörk HE. Specific C-receptors for itch in human skin. J Neurosci. 1997 Oct 15;17(20):8003-8. doi: 10.1523/JNEUROSCI.17-20-08003.1997
14. Zeidler C, Pereira MP, Huet F, Misery L, Steinbrink K, Ständer S. Pruritus in Autoimmune and Inflammatory Dermatoses. Front Immunol. 2019 Jun 21;10:1303. doi: 10.3389/fimmu.2019.01303
15. Atopic eczema in under 12s: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2023 Jun 7. (NICE Clinical Guidelines, No. 57.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK571009/
16. Eichenfield, Lawrence F. et al., Guidelines of care for the management of atopic dermatitis, Journal of the American Academy of Dermatology, Volume 70, Issue 2, 338 – 351
17. Frazier W, Bhardwaj N. Atopic Dermatitis: Diagnosis and Treatment. Am Fam Physician. 2020 May 15;101(10):590-598. PMID: 32412211.
18./ R. Chopra, P.P. Vakharia, R. Sacotte, N. Patel, S. Immaneni, T. White, R. Kantor, D.Y. Hsu, J.I. Silverberg, Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis, British Journal of Dermatology, Volume 177, Issue 5, 1 November 2017, Pages 1316–1321, https://doi.org/10.1111/bjd.15641
19. Nowicki, R. J., Trzeciak, M., Kaczmarski, M., Wilkowska, A., Czarnecka-Operacz, M., & Kowalewski, C. et al. (2019). Atopic dermatitis. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allergology, Polish Pediatric Society and Polish Society of Family Medicine. Part I. Prophylaxis, topical treatment and phototherapy. Dermatology Review/Przegląd Dermatologiczny, 106(4), 354-374. https://doi.org/10.5114/dr.2019.88253
20. National Eczema Society, https://eczema.org/information-and-advice/treatments-for-eczema/emollients/, May 15, 2025,
21. Jonathan W. Rick, Austin Morgan, Devea R. De, Jennifer L. Hsiao, Vivian Y. Shi, Allergens and marketing claims of the most popular baby moisturizers: A product analysis, Journal of the American Academy of Dermatology, Volume 88, Issue 1, 2023, p. 205-207, doi.org/10.1016/j.jaad.2022.04.034.
22. Zhu JR, Wang J, Wang SS. A single-center, randomized, controlled study on the efficacy of niacinamide-containing body emollients combined with cleansing gel in the treatment of mild atopic dermatitis. Skin Res Technol. 2023 Sep;29(9):e13475. doi: 10.1111/srt.13475.
23. Zelenkova H, Kerob D, Salah S, Demessant-Flavigny AL. Impact of daily use of emollient 'plus' on corticosteroid consumption in patients with atopic dermatitis: An open, randomized controlled study. J Eur Acad Dermatol Venereol. 2023 Jun;37 Suppl 5:27-34. doi: 10.1111/jdv.18947.
24. Heratizadeh A, Werfel T, Wollenberg A, Abraham S, Plank-Habibi S, Schnopp C, Sticherling M, Apfelbacher C, Biedermann T, Breuer K, Fell I, Fölster-Holst R, Heine G, Grimm J, Hennighausen L, Kugler C, Reese I, Ring J, Schäkel K, Schmitt J, Seikowski K, von Stebut E, Wagner N, Waßmann-Otto A, Wienke-Graul U, Weisshaar E, Worm M, Gieler U, Kupfer J; Arbeitsgemeinschaft Neurodermitisschulung für Erwachsene (ARNE) Study Group. Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial. J Allergy Clin Immunol. 2017 Sep;140(3):845-853.e3. doi: 10.1016/j.jaci.2017.01.029.
25. Singleton H, Hodder A, Almilaji O, Ersser SJ, Heaslip V, O'Meara S, Boyers D, Roberts A, Scott H, Van Onselen J, Doney L, Boyle RJ, Thompson AR. Educational and psychological interventions for managing atopic dermatitis (eczema). Cochrane Database Syst Rev. 2024 Aug 12;8(8):CD014932. doi: 10.1002/14651858.CD014932.pub2.
26. Andrade LF, Abdi P, Mashoudy KD, Kooner A, Egler A, Urbonas R, Smith A, Yosipovitch G. Effectiveness of atopic dermatitis patient education programs - a systematic review and meta-analysis. Arch Dermatol Res. 2024 Apr 25;316(5):135. doi: 10.1007/s00403-024-02871-y.
27. Zhao M, Liang Y, Shen C, Wang Y, Ma L, Ma X. Patient Education Programs in Pediatric Atopic Dermatitis: A Systematic Review of Randomized Controlled Trials and Meta-Analysis. Dermatol Ther (Heidelb). 2020 Jun;10(3):449-464. doi: 10.1007/s13555-020-00365-z.
28. Sy W, Bhayana M, Lamb AJ. Atopic Dermatitis Disease Education. Adv Exp Med Biol. 2024;1447:209-215. doi: 10.1007/978-3-031-54513-9_17.
29. Caubet JC, Eigenmann PA. Allergic triggers in atopic dermatitis. Immunol Allergy Clin North Am. 2010 Aug;30(3):289-307. doi: 10.1016/j.iac.2010.06.002.
30. Bremmer SF, Simpson EL. Dust mite avoidance for the primary prevention of atopic dermatitis: A systematic review and meta-analysis. Pediatr Allergy Immunol. 2015 Nov;26(7):646-54. doi: 10.1111/pai.12452.
31. Singh AM, Anvari S, Hauk P, Lio P, Nanda A, Sidbury R, Schneider L. Atopic Dermatitis and Food Allergy: Best Practices and Knowledge Gaps-A Work Group Report from the AAAAI Allergic Skin Diseases Committee and Leadership Institute Project. J Allergy Clin Immunol Pract. 2022 Mar;10(3):697-706. doi: 10.1016/j.jaip.2021.12.037.
32. Wassmann-Otto A, Heratizadeh A, Wichmann K, Werfel T. Birch pollen-related foods can cause late eczematous reactions in patients with atopic dermatitis. Allergy. 2018 Oct;73(10):2046-2054. doi: 10.1111/all.13454.
33. Butala S, Paller AS. Optimizing topical management of atopic dermatitis. Ann Allergy Asthma Immunol. 2022 May;128(5):488-504. doi: 10.1016/j.anai.2022.03.004.
34. Pofi R, Caratti G, Ray DW, Tomlinson JW. Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad? Endocr Rev. 2023 Nov 9;44(6):975-1011. doi: 10.1210/endrev/bnad016.
35. Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol. 2005;6(2):65-77. doi: 10.2165/00128071-200506020-00001.
36. Abędź N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. Postepy Dermatol Alergol. 2019 Dec;36(6):752-759. doi: 10.5114/ada.2019.91425.
37. Paller AS, Fölster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ, Pollock BH. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020 Aug;83(2):375-381. doi: 10.1016/j.jaad.2020.03.075.
38. Castellsague J, Kuiper JG, Pottegård A, Anveden Berglind I, Dedman D, Gutierrez L, Calingaert B, van Herk-Sukel MP, Hallas J, Sundström A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). Clin Epidemiol. 2018 Mar 13;10:299-310. doi: 10.2147/CLEP.S146442.
39. Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, Purohit VS, Zielinski MA, Vlahos B, Estrada YD, Saint-Cyr Proulx E, Ports WC, Guttman-Yassky E. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial. J Allergy Clin Immunol. 2019 Nov;144(5):1274-1289. doi: 10.1016/j.jaci.2019.06.047.
40. Ahluwalia J, Udkoff J, Waldman A, Borok J, Eichenfield LF. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook. Drugs. 2017 Sep;77(13):1389-1397. doi: 10.1007/s40265-017-0784-3.
41. Mazgaj J, Kotewicz M, Jaworek A, Szepietowski JC. The future of topical JAK inhibitors in the treatment of atopic dermatitis. Expert Opin Pharmacother. 2025 Mar;26(4):473-480. doi: 10.1080/14656566.2025.2465869.
42. Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021 Oct;148(4):927-940. doi: 10.1016/j.jaci.2021.08.009.
43. Molla A. A Comprehensive Review of Phototherapy in Atopic Dermatitis: Mechanisms, Modalities, and Clinical Efficacy. Cureus. 2024 Mar 25;16(3):e56890. doi: 10.7759/cureus.56890.
44. Patrizi A, Raone B, Ravaioli GM. Safety and Efficacy of Phototherapy in the Management of Eczema. Adv Exp Med Biol. 2017;996:319-331. doi: 10.1007/978-3-319-56017-5_27.
45. Ahad T, Wang EY, Liu YA, Lee TK, Lui H, Crawford RI, Kalia S. Incidence of skin cancers in patients with eczema treated with ultraviolet phototherapy. J Am Acad Dermatol. 2022 Aug;87(2):387-389. doi: 10.1016/j.jaad.2021.11.048.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Damian Osiński, Zuzanna Kawa, Maria Kasprzak, Aleksandra Jędrzejewska, Aleksandra Jureczko, Klaudia Kleczaj, Valentyna Levadna, Julia Jaworowska, Gabriela Babiarz, Julia Kanarszczuk

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 128
Number of citations: 0